$4.97
-0.22 (-4.24%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where QNRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 1 tracked-famous manager (MILLENNIUM MANAGEMENT LLC) · FINRA short interest 10.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeNCT07538583Proportion of subjects with 1-point reduction on IGAOpen-label · Treatment | Phase 2/3 | Recruiting | Drug: QRX003 | Netherton Syndrome | 16 | 2027-01-31 | in 165 d | 2026-04-21 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeNCT06953466Proportion of subjects with 1-point reduction on IGAOpen-label · Treatment | Phase 2/3 | Recruiting | Drug: QRX003, 4% Lotion | Netherton Syndrome | 8 | 2026-07-30 | — | 2025-07-20 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeNCT05521438Efficacy Endpoints-1-point IGARandomized · Triple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID | Netherton Syndrome | 30 | 2025-12-30actual | — | 2026-03-16 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeNCT05789056Proportion of subjects with 1-point reduction on IGANon-randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: QRX003, 4% Lotion | Netherton Syndrome | 20 | 2025-12-30 | — | 2025-04-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19